Navigation Links
Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting

WALTHAM, Mass., June 5 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that Nazneen Aziz, Ph.D., Vice President of Research and Development, will present findings that highlight significant associations between perilipin gene variants and response to weight-loss in overweight individuals at the American Diabetes Association's 69th Scientific Sessions in New Orleans, LA. Dr. Aziz will present the Company's research at 8 a.m. on Saturday, June 6, 2009, in Room 255 of the Morial Convention Center.

Interleukin Genetics and its collaborators conducted the research on DNA samples from the NIH-sponsored CALERIE (Comprehensive Assessment of the Long Term Effects of Restricting Intake of Energy) pilot study. CALERIE evaluated high and low glycemic load with a 30 percent calorie-restricted diets in individuals during a tightly-controlled, one-year period. The diets were prepared at the institution and provided to the study subjects for a period of six months and followed by extensive dietary guidance for the next six months. Compliance to the diet was monitored using a non-radioactive isotope mass spectrometric method using doubly labeled water technique several times during the study period. The Company's research found that variations within the Perilipin genes are associated with resistance to body weight and fat loss in overweight study subjects who were provided a calorie restricted diet.

"Perilipin is a protein in the phospholipid outer layer of fat cells that plays an important role in both the storage and metabolism of triglycerides. This study confirms the results of other dietary intervention studies that found certain genetic variants within the perilipin gene can cause resistance to weight loss in individuals even when they follow a low-carbohydrate, low-calorie diet plan for an extended period," said Dr. Aziz. "We hope to further extend these findings with broader studies, as these specific genotype considerations can lend themselves to possible clinical utility in optimal weight-loss programs for the obese/overweight population.

Interleukin Genetics genotyped a panel of 23 SNPs within genes involved in fat and carbohydrate metabolism in the study subjects who had consented for genetic analysis. A linear regression model that adjusted for age, gender and high or low glycemic dietary groups was used for the association analysis. Findings concluded that PLIN1/C and PLIN4/A showed resistance to body weight and fat loss in subjects provided a low glycemic load, 30 percent calorie restricted diet.

About American Diabetes Association

The American Diabetes Association is leading the fight against the deadly consequences of diabetes and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent chronic diseases of aging and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property, and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit

Certain statements contained herein are "forward-looking" statements including statements regarding the Company's ability to develop genetic tests that identify genetic variations that affect optimal weight-loss methods, to identify nutritional and lifestyle decisions that favorably affect such conditions, to provide such information in a format tailored to the individual, and to otherwise make progress in advancing the Company's core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those risks and uncertainties described in the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. T cell immunity enhanced by timing of interleukin-7 therapy
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
6. Interleukin-12 indicates survival prospects for melanoma patients
7. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
9. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
10. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
11. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Sir Grout of Greater Boston donated an expansive, ... of Ronald McDonald House Charities® (RMHC®). This donation was made in an effort to ... Boston since its inception. , “We believe strongly in the Ronald McDonald House Charities, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology company ... health programs and interventions via mobile devices that provide a framework for the ...
(Date:10/13/2015)... ... 13, 2015 , ... Element Blue ™, a leading ... company, RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom ... approach for customers requiring sensor hardware for critical data environments. , RightSensor™, working ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... NavaFit Inc. ... helps individuals find others to train with, participate in local fitness & sporting ... and Google Play. , “As high medical costs drive us to get more serious ...
(Date:10/13/2015)... (PRWEB) , ... October 13, ... ... Postnatal Omega-3, a first-of-its kind product that targets the unique health needs ... Omega-3” of the American Pregnancy Association ( ), utilizes Nordic Naturals’ ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...   Rosa & Co. LLC , the leading ... (QSP)/ PhysioPD™ , today announced that Dr. Christina ... the QSP Congress Meeting on October 20 ...  The conference focuses on the uses and benefits ... is entitled "Using Mechanistic Physiological Models in Drug Development: ...
(Date:10/13/2015)... 13, 2015 China Jo-Jo Drugstores, ... Jo-Jo "), a leading China-based retail, wholesale and online ... own online and retail pharmacies, announced preliminary half year ... online pharmacy through , growing 438% year ... 25%. China Jo-Jo,s online sales ...
(Date:10/13/2015)... N.C. , Oct. 13, 2015  Yesterday Congresswoman ... Influenza Vaccines Holly Springs manufacturing site located in ... 2014, the facility has produced Flucelvax ® (Influenza ... the potential for faster start-up and is not reliant ... CSL Limited acquired the influenza vaccines business of Novartis ...
Breaking Medicine Technology: